AML/MDS

Our research and trials staff are dedicated and experienced professionals, interested in pushing the boundaries of our knowledge and testing new ideas in practical environments. Use the links below to jump to categorised trials.

AML17 (closed to recruitment)
Type: NCRI, multi-centre Phase III randomised trial
Eligibility: Newly diagnosed AML, APML or high risk MDS with >10% blasts (RAEB-2) Age 18 – 60 years (No upper age limit specified for APML patients) Selected patients > 60 years age if fit for intensive chemotherapy
Study details: Compares several different induction and consolidation approaches including use of some novel drugs in a risk adapted/ randomised manner.
AML16 (closed to recruitment)
Type: NCRI, multi-centre Phase III randomised trial
Eligibility: Newly diagnosed AML or high risk MDS with >10% blasts (RAEB-2) Age > 60 years Selected patients < 60 years if unsuitable for intensive treatment in AML 17 NB: Patients with ALML are excluded
Study details: Compares several different induction and consolidation approaches including use of some novel drugs in a randomised manner.
AML18 (pilot) – (closed to recruitment)
Type: Pilot Study
Eligibility: A Phase 1B/2 Study to Evaluate the Feasibility of combining either the Tyrosine kinase Inhibitor AC220, or the CXCR4 inhibitor Plerixafor with Chemotherapy in older patient with Acute Myeloid Leukaemia and Myelodysplastic Syndrome in patient over 60 years
Study details: The AML 18 Pilot Trial is available to any patient who has primary or secondary AML defined by the WHO Classification (excluding Acute Promyelocytic Leukaemia), or high risk Myelodysplastic Syndrome (i.e. > 10% marrow blasts) who is not considered suitable for the current NCRI trial for younger patients (MRC AML 17).
LI-1 
Type: Multi-centre randomised Phase II study
Eligibility: Older patients with Acute Myeloid Leukaemia and high risk Myelodsyplastic Syndrome
Study details: The AML LI-1 is availables to any patient who has primary or secondary AML as defined by the WHO Classification (exluding Acute Promyelocytic Leukaemia), or high risk Myelodysplastic Syndrome (i.e. ? 10% marrow blasts) who is not considered suitable for the current NCRI trial for older patients who are suitable for intensive chemothraphy (currently NCRI AML 16).